Therakos, a subsidiary of Mallinckrodt Pharmaceuticals, specializes in providing advanced photopheresis systems and procedural kits used in immunotherapy treatments. The company operates in the healthcare sector, primarily serving hospitals, clinics, and medical professionals who treat patients with immune system disorders. Therakos' core product, the THERAKOS Photopheresis System, is designed to support extracorporeal photopheresis (ECP) procedures, which involve the exposure of blood to UVA light to treat various conditions. The company ensures that its procedural kits are manufactured in a controlled environment, adhering to stringent clean room standards to maintain product integrity and patient safety. Therakos generates revenue through the sale of its photopheresis systems, procedural kits, and related consumables. The business model focuses on maintaining a robust supply chain and close communication with customers to ensure continuous product availability, even during crises such as the COVID-19 pandemic. Key clients include healthcare providers who require reliable and effective immunotherapy solutions.

Keywords: photopheresis, immunotherapy, healthcare, procedural kits, UVA light, immune disorders, clean room, medical equipment, supply chain, patient safety.